Shots: Mylan to get manufacturing & commercialization rights of pretomanid in BPaL regimen (bedaquiline, pretomanid and linezolid for 6-9 mos.) for XDR & MDR-TB. Janssen to hold the rights for […]readmore
Tags : Collaborates
Shots: PureTech to receive $26M as an upfront including research funding & preclinical milestone, $200M as development and commercial milestones and royalties on sales. Boehringer to develop immune-oncology candidates after […]readmore
Shots: Insitro to receive $15M upfront, $35M near term operational milestone, $200M as preclinical, development, regulatory and commercial milestones on each 5 targets & royalties on sales. Insitro has also […]readmore
Shots: Thermo Fisher and NX Prenatal enter into a collaboration to develop proteomics assays by combining NX Prenatal’s NeXosome platform with Thermo Fisher’s LC-MS instrumentation for monitoring the maternal & […]readmore
Shots: Tessa to conduct a P-Ib/II trial assessing Tessa’s human papillomavirus-specific T cell (HPVST) therapy or TT12 with Merck’s Keytruda (pembrolizumab) for patients with recurrent or metastatic HPV 16 and […]readmore
Shots: Fibrocell to receive $7.5M upfront, $2.5M on first patient enrollment, $30M on BLA approval, $75M as commercial milestones and 30% of profit on product sales. Castle Creek to get […]readmore
Shots: Sandoz to get commercialization rights for Rizmoic (naldemedine) in Germany, UK and the Netherlands with rights of first refusal for other European markets. Shionogi will be responsible for Rizmoic’s […]readmore
Shots: Astellas partners with Concerto HealthAI to uitilize Concerto’s RWD in order to track the response in patients with FLT3 mutation-positive r/r AML The companies will utilize ASCO’s CancerLinQ […]readmore
Shots: Audentes and NCH enter into a license agreement to develop AT702 designed to induce exon 2 skipping in DMD patients with exon 2 duplications and mutations in exons 1-5 […]readmore
Shots: Alnylam & Regeneron to co-discover RNAi therapies for eye and CNS diseases. Alnylam to receive $400M upfront, $400M equity at a price of $90/share, $200M as milestones and royalties […]readmore